Clinical Feature	N	Included N=1770 N±SD (%)	Excluded N=575 N±SD (%)	P
Demographics				
Age (Years)	2345	41±15	40±15	0.15
Gender (% Female)	2345	1221(69.0)	405(70.4)	0.55
APAP Etiology of ALF	2345	798(45.1)	283(49.2)	0.09
Clinical Features on Admission				
Plasma before admission	2268	762(44.3)	205(37.4)	0.005
Anticoagulants on admission	2345	46(2.6)	17(3.0)	0.756
Aspirin on admission	2345	100(5.6)	35(6.1)	0.77
SIRS (% ≥2)	1780	1024(75.1)	286(68.8)	0.013
Encephalopathy Grade 3/4	2274	848(49.3)	202(36.5)	< 0.001
INR^	2025	2.8±2.2	2.5±1.6	0.001
Platelet Count ($x10^9$/L)^	2012	124.0±109.0	137.0±84.0	0.002
WBC ($x10^9$/L)	2321	10.2±8.3	10.2±7.5	0.73
Hemoglobin (g/dl)	2318	10.9±3.1	11.1±3.3	0.14
Clinical Features and Interventions after Admission, Days 1-7				
Bleeding Complication*	2339	187(10.6)	42(7.4)	0.032
RBC Transfusion	2345	651(36.8)	148(25.7)	< 0.001
Plasma Transfusion	2345	994(56.2)	238(41.4)	< 0.001
Platelet Transfusion	2345	435(24.6)	71(12.3)	< 0.001
Outcomes at Day 21				
Liver Transplantation	2331	430(24.5)	117(20.4)	0.051
Died†	2107	599(33.8)	73(21.7)	< 0.001
COD Bleeding†	672	16(2.7)	1(1.4)	1.00

** Excludes N=6 subjects with missing bleeding data*
^ Excludes N=331 subjects with missing platelet and/or INR data
†Excludes N=238 subjects with unknown 21 day status

Supplemental Table 1. **Comparison of patients included and excluded from the study.** (COD, cause of death).



Supplemental Figure 1. **Patient accrual according to outcome at day 21, and distribution of bleeding complications.**



Supplemental Figure 2. **Percentage of patients enrolled into the ALF Study Group Registry who received blood products (RBC, plasma, and/or platelets; upper line) and who experienced bleeding complications (lower line) between days 1-7 by year of enrollment.**